Clinical Trial Update: Study of CP-675,206 in Refractory Melanoma [Phase 2]

View source ↗

Summary

Phase 2 study of CP-675,206 in refractory melanoma has completed. The provided snippet does not include results or outcomes from the trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• CP-675,206

Snippet

Sponsor: AstraZeneca | Conditions: Refractory Melanoma | Phase 2 | Status: COMPLETED